Abstract
Aim. To evaluate the efficacy of pimecrolimus cream 1% in patients with facial psoriasis. Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1%. The drug has been applied to the facial lesions twice daily for 2 months. Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5% of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5% of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug. Conclusions. In our study pimecrolimus cream 1% has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.
| Original language | English |
|---|---|
| Pages (from-to) | 415-419 |
| Number of pages | 5 |
| Journal | Giornale Italiano di Dermatologia e Venereologia |
| Volume | 141 |
| Issue number | 4 |
| Publication status | Published - 2006 |
Fingerprint
Keywords
- Face
- Pimecrolimus
- Psoriasis, drug therapy
ASJC Scopus subject areas
- Dermatology
Cite this
The use of pimecrolimus cream 1% in the treatment of facial psoriasis. / Frigerio, E.; Taglioni, M.; Franchi, C.; Garutti, C.; Spadino, S.; Altomare, A.; Altomare, G. F.
In: Giornale Italiano di Dermatologia e Venereologia, Vol. 141, No. 4, 2006, p. 415-419.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The use of pimecrolimus cream 1% in the treatment of facial psoriasis
AU - Frigerio, E.
AU - Taglioni, M.
AU - Franchi, C.
AU - Garutti, C.
AU - Spadino, S.
AU - Altomare, A.
AU - Altomare, G. F.
PY - 2006
Y1 - 2006
N2 - Aim. To evaluate the efficacy of pimecrolimus cream 1% in patients with facial psoriasis. Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1%. The drug has been applied to the facial lesions twice daily for 2 months. Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5% of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5% of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug. Conclusions. In our study pimecrolimus cream 1% has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.
AB - Aim. To evaluate the efficacy of pimecrolimus cream 1% in patients with facial psoriasis. Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1%. The drug has been applied to the facial lesions twice daily for 2 months. Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5% of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5% of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug. Conclusions. In our study pimecrolimus cream 1% has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.
KW - Face
KW - Pimecrolimus
KW - Psoriasis, drug therapy
UR - http://www.scopus.com/inward/record.url?scp=33749468546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749468546&partnerID=8YFLogxK
M3 - Article
VL - 141
SP - 415
EP - 419
JO - Minerva dermatologica
JF - Minerva dermatologica
SN - 0392-0488
IS - 4
ER -